| 摘要 |
Method for diagnosing presence and/or severity of liver disease and/or for monitoring efficacy of its treatment by establishing at least one non-invasive diagnostic score (S), particularly diagnostic of portal and septal fibrosis and/or an estimate of area of fibrosis and/or of fractal dimension. Method for diagnosing presence and/or severity of liver disease and/or for monitoring efficacy of its treatment by establishing at least one non-invasive diagnostic score (S), particularly diagnostic of portal and septal fibrosis and/or an estimate of area of fibrosis and/or of fractal dimension comprises: (a') to assess area of fibrosis and fractal dimension, determining at least one of the variables alpha 2-macroglobulin (A2M); hyaluronic acid (HA); apolipoprotein A1 (Apa1); N-terminal peptide of procollagen type III (P3P); gamma -glutamyltranspeptidase (GGT); bilirubin; platelets (PLQ), prothrombin (PT); aspartate aminotransferase (ASAT); alanine aminotransferase (ALAT); urea; sodium; glycemia; triglycerides; albumen (ALB); human cartilage glycoprotein 39 (YAK-40); tissue inhibitor of matrix metalloprotease 1 (TIMP1); matrix metalloprotease 2 (MMP-2) and ferritin; (a) to establish a diagnostic score of portal and septal fibrosis, determining at least 3 of the variables specified in (a1), provided that at least one is PLQ or TP; (b) optionally determining at least one clinical variable characteristic of the patient; (c) combining, in a logistic or linear form, at least 4 variables of (a) and optionally variables of (b) to obtain a score (S); and (d) using (S) to diagnose disease and/or severity, or effect of treatment. |
